Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) EBIT Margin (2017 - 2025)

Crinetics Pharmaceuticals has reported EBIT Margin over the past 9 years, most recently at 2169.55% for Q4 2025.

  • For Q4 2025, EBIT Margin changed N/A year-over-year to 2169.55%; the TTM value through Dec 2025 reached 6714.77%, up 2589870.0%, while the annual FY2025 figure was 6714.77%, 2589870.0% up from the prior year.
  • EBIT Margin for Q4 2025 was 2169.55% at Crinetics Pharmaceuticals, up from 99710.49% in the prior quarter.
  • Over five years, EBIT Margin peaked at 1080.39% in Q1 2022 and troughed at 99710.49% in Q3 2025.
  • A 5-year average of 16546.14% and a median of 9646.51% in 2022 define the central range for EBIT Margin.
  • On a YoY basis, EBIT Margin climbed as much as 822463bps in 2025 and fell as far as -1937120bps in 2025.
  • Year by year, EBIT Margin stood at 2865.31% in 2021, then tumbled by -134bps to 6707.48% in 2022, then plummeted by -154bps to 17045.38% in 2023, then decreased by -22bps to 20747.62% in 2024, then skyrocketed by 90bps to 2169.55% in 2025.
  • Business Quant data shows EBIT Margin for CRNX at 2169.55% in Q4 2025, 99710.49% in Q3 2025, and 12522.99% in Q2 2025.